Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru

Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), has received a EU GMP certificate from the Health Products Regulatory Authority (HPRA), Ireland, for its new monoclonal antibodies (mAbs) drug substance manufacturing facility (B3) at Biocon Park, Bengaluru, following a GMP inspection in April 2022.

The facility, spread across 340,000-square feet, will enhance our capabilities manifold to manufacture drug substance of our mAbs portfolio and will enable us to serve patients across the globe. This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.

Upon successful completion and qualification in 2021, it was awarded the Facility of the Year Award (FOYA) with a Honorable Mention, by the International Society for Pharmaceutical Engineering's (ISPE).

Shares of Biocon Limited was last trading in BSE at Rs. 313.70 as compared to the previous close of Rs. 311.20. The total number of shares traded during the day was 252381 in over 2010 trades.

The stock hit an intraday high of Rs. 316.60 and intraday low of 311.75. The net turnover during the day was Rs. 79561108.00.

Source : Equity Bulls

Keywords

BioconBiologics Biocon INE376G01013 EUGMP HPRA Ireland monoclonalantibodies GMPInspection